ICICI Direct: Pfizer Posts Steady Q2 Performance Amid Divestiture, Disturbances  
Signage is displayed in the window of the Pfizer Inc. Research and Development Center in Cambridge, Massachusetts, U.S. (Photographer: Scott Eisen/Bloomberg)

ICICI Direct: Pfizer Posts Steady Q2 Performance Amid Divestiture, Disturbances  


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Pfizer Ltd.’s Q2 FY21 revenues grew 5% YoY to Rs 595 crore.

Adjusting for divesture of rights and interests in certain brands and Covid-19, YoY growth for the quarter was at 10.1%.

Also, hospital and vaccines business reflected improved performance due to easing of lockdown.

Ebitda margins expanded 520 basis points to 34.1% YoY due to a better overall operational performance.

Click on the attachment to read the full report:

ICICI Direct Pfizer Company Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.